AMS announced its Interim results for the six months ended 30 June 2025 This week Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2025. Group revenue increased by 63% to £110.8 million and by 66% at constant currency […]
AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]
– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]
During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm. Novo […]
EMERALD Study will investigate safety and efficacy of engineered macrophage cell therapy in patients with decompensated liver cirrhosis Edinburgh and London, UK, 27 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease today announces it has received approval from the U.K. Medicines and Healthcare […]
